We are live on
!
Find out more
CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.67B
1-Year Est. Return
89%
This Fund
S&P 500
This Quarter
Est. Return
+18.11%
1 Year Est. Return
+89%
3 Year Est. Return
+264.17%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$514M
AUM Growth
+$169M
(+49%)
Cap. Flow
+$103M
Cap. Flow
% of AUM
19.96%
Top 10 Holdings %
Top 10 Hldgs %
26.88%
Holding
503
New
57
Increased
239
Reduced
90
Closed
78
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$6.25M |
| 2 |
Gilead Sciences
GILD
|
+$6.13M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$6.05M |
| 4 |
Amgen
AMGN
|
+$5.9M |
| 5 |
Adobe
ADBE
|
+$5.02M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.85M |
| 2 |
Analog Devices
ADI
|
+$3.37M |
| 3 |
Amazon
AMZN
|
+$3.21M |
| 4 |
lululemon athletica
LULU
|
+$2.87M |
| 5 |
Oracle
ORCL
|
+$1.91M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 34.39% |
| 2 | Healthcare | 30.05% |
| 3 | Consumer Discretionary | 17.55% |
| 4 | Communication Services | 6.11% |
| 5 | Consumer Staples | 4.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TERN
376
DELISTED
Terns Pharmaceuticals
TERN
| $46.4K | 0.01% |
7,147
+5,587
| +358% | +$29.5K |
|
377
SIGA Technologies
SIGA
$206M
| $46.1K | 0.01% |
8,225
+6,404
| +352% | +$34.3K |
|
378
Harrow
HROW
$1.48B
| $45.5K | 0.01% |
4,063
+3,155
| +347% | +$37.3K |
|
|
ITOS
379
DELISTED
iTeos Therapeutics
ITOS
| $45.3K | 0.01% |
4,140
+3,216
| +348% | +$31.9K |
|
|
WBA
380
DELISTED
Walgreens Boots Alliance
WBA
| $44.8K | 0.01% |
1,715
-1,502
| -47% | -$33.6K |
|
381
Lexicon Pharmaceuticals
LXRX
$1.05B
| $43.3K | 0.01% |
28,329
+22,043
| +351% | +$26.2K |
|
382
Nautilus Biotechnolgy
NAUT
$114M
| $43.2K | 0.01% |
14,452
+11,248
| +351% | +$32.2K |
|
383
Voyager Therapeutics
VYGR
$197M
| $43K | 0.01% |
+5,093
| New | +$36.9K |
|
384
Coherus Oncology
CHRS
$181M
| $42.9K | 0.01% |
12,880
+10,454
| +431% | +$28K |
|
385
uniQure
QURE
$3.13B
| $42.4K | 0.01% |
6,258
+4,315
| +222% | +$28.5K |
|
386
SiriusXM
SIRI
$9.59B
| $42.1K | 0.01% |
770
-662
| -46% | -$31.8K |
|
387
Ocular Therapeutix
OCUL
$2.25B
| $41K | 0.01% |
9,192
+7,152
| +351% | +$21.1K |
|
388
Mineralys Therapeutics
MLYS
$2.38B
| $40.9K | 0.01% |
+4,750
| New | +$37.3K |
|
389
Unity
U
$19.6B
| $39.3K | 0.01% |
961
| – | – |
|
|
AMRN
390
Amarin Corp
AMRN
$297M
| $38.8K | 0.01% |
2,230
+1,736
| +351% | +$27.2K |
|
391
Precigen
PGEN
$2.45B
| $38.6K | 0.01% |
28,788
+22,227
| +339% | +$26.1K |
|
392
Taysha Gene Therapies
TSHA
$2.05B
| $38.3K | 0.01% |
+21,622
| New | +$43.1K |
|
393
Xeris Biopharma Holdings
XERS
$1.55B
| $37.5K | 0.01% |
15,973
+12,432
| +351% | +$22.9K |
|
394
Erasca
ERAS
$6.45B
| $37.2K | 0.01% |
17,472
+13,597
| +351% | +$28.7K |
|
395
Align Technology
ALGN
$12.4B
| $36.4K | 0.01% |
133
-285
| -68% | -$67.6K |
|
396
Arcutis Biotherapeutics
ARQT
$3.3B
| $35.3K | 0.01% |
10,920
+9,330
| +587% | +$25.4K |
|
|
YMAB
397
DELISTED
Y-mAbs Therapeutics
YMAB
| $34.4K | 0.01% |
+5,050
| New | +$29.2K |
|
398
Humacyte
HUMA
$179M
| $34K | 0.01% |
11,986
+9,325
| +350% | +$23.9K |
|
|
EXAI
399
DELISTED
Exscientia Plc American Depositary Shares
EXAI
| $33.6K | 0.01% |
5,245
+4,104
| +360% | +$23.2K |
|
|
ME
400
DELISTED
23andMe Holding Co
ME
| $32.9K | 0.01% |
1,802
+1,411
| +361% | +$24.4K |
|
Similar funds
HA
JPM
CPO
LCI
GWM
JIP
RMC
GACM
China Universal Asset Management Company's Q4 2023 Portfolio in Review
As of Q4 2023, China Universal Asset Management Company held 503 positions worth $514M, up 49% from $345M the previous quarter. Its ten largest holdings account for 27% of the portfolio.
China Universal Asset Management Company deployed $103M of net new capital in Q4 2023, opening 57 new positions and adding to 239 existing holdings. Its largest new stake was GSK: 54,345 shares worth $2.03M.
By sector, the portfolio is most concentrated in Technology at 34% of assets, down from 38% a quarter earlier, followed by Healthcare and Consumer Discretionary.
On the sell side, the largest reduction was NVIDIA, an estimated $4.85M trimmed.
- China Universal Asset Management Company's largest Q4 2023 buy was GSK: 54,345 shares worth $2.03M.
- China Universal Asset Management Company added most to Vertex Pharmaceuticals in Q4 2023, an estimated $6.25M increase.
- China Universal Asset Management Company's biggest Q4 2023 reduction was NVIDIA, cutting an estimated $4.85M.
- China Universal Asset Management Company fully exited Oracle in Q4 2023, selling an estimated $1.91M.
- China Universal Asset Management Company's ten largest holdings make up 27% of its $514M portfolio in Q4 2023.
- China Universal Asset Management Company opened 57 new positions and closed 78 in Q4 2023.
- China Universal Asset Management Company's portfolio value rose 49% quarter-over-quarter to $514M.
Based on China Universal Asset Management Company's 13F filing for Q4 2023, filed 24 Jan 2024.